Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The recommended dose of BARI is 4 mg once daily.
A dose of 2 mg once daily is appropriate for
patients such as those aged ≥ 75 years and may be appropriate for patients with a history of chronic or recurrent infections.
patients who have achieved sustained control of disease activity with 4 mg once daily and are eligible for dose tapering.1
patients with creatinine clearance (eGFR) between 30 and 60 mL/min.1
patients taking OAT3 inhibitors with a strong inhibition potential, such as probenecid, is 2 mg once daily.1
Use of BARI is not recommended in patients with
estimated glomerular filtration rate of < 30 mL/min/1.73 m2.
severe hepatic impairment
absolute lymphocyte count <500 cells/mm3
absolute neutrophil count <1000 cells/mm3, or
hemoglobin level <8 g/dL.1
Use of BARI is not recommended in pediatric patients.1
Route of administration
Baricitinib is an oral drug to be given daily.1
1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M04 30